Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin

Cancer. 1982 Mar 15;49(6):1174-7. doi: 10.1002/1097-0142(19820315)49:6<1174::aid-cncr2820490618>3.0.co;2-w.

Abstract

Sixty-one patients with epidermoid carcinoma of the esophagus have been treated with a three drug combination of cisplatin, vindesine, and bleomycin. Of 53 patients currently evaluable for response, 29 (55%) have had partial remissions: 7/16 with metastatic, and 22/37 with local-regional disease. The median duration of response in metastatic patients is eight months. Of 28 patients treated preoperatively, 23 (82%) had resectable disease. The major toxicities seen were nephrotoxicity and myelosuppression. Cisplatin, vindesine and bleomycin is an effective combination in the treatment of esophageal carcinoma. Effects on long-term survival cannot yet be evaluated.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Bleomycin / administration & dosage*
  • Bleomycin / adverse effects
  • Carcinoma, Squamous Cell / drug therapy*
  • Cisplatin / administration & dosage*
  • Cisplatin / adverse effects
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Esophageal Neoplasms / drug therapy*
  • Female
  • Humans
  • Leukopenia / chemically induced
  • Male
  • Vinblastine / administration & dosage
  • Vinblastine / adverse effects
  • Vinblastine / analogs & derivatives*
  • Vindesine

Substances

  • Bleomycin
  • Vinblastine
  • Cisplatin
  • Vindesine